Drug research

Plozasiran

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as ARO-APOC3

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisNCT06880770	Arrowhead Pharmaceuticals	Phase 3	Recruiting	2029-03Estimated
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)NCT05089084	Arrowhead Pharmaceuticals	Phase 3	Completed	2024-04-29Actual

Arrowhead PharmaceuticalsRecruitingPrimary completion: 2029-03 · Estimated

Trial details

Arrowhead PharmaceuticalsCompletedPrimary completion: 2024-04-29 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.